HYPOXEMIA

Hypoxemia is a condition caused by injury to the lungs, which can be caused by nasal and respiratory diseases, infections, cancer, toxic chemicals, ozone, and many medications all of which reduces oxygen levels to the whole body, producing fatigue, coughing, trouble breathing and shortness of breath (dyspnea) and a decrease in lung functions.

Hypoxemia is manifested in COVID-19 infected patients, in patients with Long COVID, Pulmonary Fibrosis and Flu.

Worldwide Patented N115 Non-Steroidal Nasal Spray Drug with no known side effects:

Numerous studies have shown oxidative stress to be associated with many Nasal and Interstitial Lung Diseases and that antioxidants are effective in attenuating fibroproliferative responses in the lungs of animals and humans. Sodium Pyruvate (N115 Nasal Spray) is a natural antioxidant of the human body and as an antioxidant it has been shown to significantly reduce inflammatory agents throughout the human body including the lungs and nasal passages.

To date, N115, has demonstrated efficacy, with no known side effects, for all lung and sinus diseases tested including:  COPD, Pulmonary Fibrosis, CF, Allergic Rhinitis, Chronic Rhinitis, Sinusitis, COVID-19, long COVID, and Flu.

In 19 Human Clinicals (Phase I, II, III including animal safety data) submitted to the FDA, N115 produced statistically significant increases in all lung functions with the reduction in nasal and respiratory inflammation, a reduction in oxygen radicals, congestion, coughing, fatigue, and a reduction of inflammatory cytokines including IL-6, a cause of the cytokine storm in COVID-19 patients.

N115 also increases the synthesis of nasal nitric oxide, a natural defence molecule that kills invading bacteria, fungi, and viruses to prevent and reduce the severity of infections.

N115 produces statistically and clinically significant reduction of the symptoms in patients with hypoxemia, fatigue, headaches, coughing, trouble breathing and shortness of breath (dyspnea), while reducing viral titers in COVID-19 and FLU patients.

Thousands of Patients have been tested in 19 Phase I,II,III Human Clinical Trials and the results submitted to the FDA.